Table 1.
Sample characteristics for advanced renal cell carcinoma and advanced prostate cancer patients
| Advanced renal cell carcinoma (study group) | Advanced prostate cancer (control group) | |||||
|---|---|---|---|---|---|---|
| Diagnosed in 2000–2005 | Diagnosed in 2006–2010 | P‐value | Diagnosed in 2000–2005 | Diagnosed in 2006–2010 | P‐value | |
| Total (N) | 7231 | 6439 | 13,924 | 12,066 | ||
| Age (mean, SD) | 65.6 (12.8) | 65.7 (12.8) | 0.77 | 72.6 (11.1) | 71.9 (11.6) | <0.01 |
| Age group (%) | ||||||
| 18–54 | 1506 (20.8%) | 1265 (19.6%) | 0.01 | 879 (6.3%) | 853 (7.1%) | <0.01 |
| 55–64 | 1885 (26.1%) | 1830 (28.4%) | 2522 (18.1%) | 2630 (21.8%) | ||
| 65–74 | 1869 (25.8%) | 1600 (24.8%) | 3943 (28.3%) | 3224 (26.7%) | ||
| 75 and up | 1971 (27.3%) | 1744 (27.1%) | 6580 (47.3%) | 5359 (44.4%) | ||
| Gender (%) | ||||||
| Female | 2564 (35.5%) | 2221 (34.5%) | 0.02 | |||
| Male | 4667 (64.5%) | 4218 (65.5%) | 13,924 (100.0%) | 12,066 (100.0%) | ||
| Race (%) | ||||||
| White | 6183 (85.5%) | 5395 (83.8%) | <0.01 | 10,399 (74.7%) | 9061 (75.1%) | 0.04 |
| Black | 689 (9.5%) | 594 (9.2%) | 2630 (18.9%) | 2153 (17.8%) | ||
| Other | 349 (4.8%) | 438 (6.8%) | 775 (5.6%) | 747 (6.2%) | ||
| Missing | 10 (0.1%) | 12 (0.2%) | 120 (0.9%) | 105 (0.9%) | ||
| Marital status (%) | ||||||
| Married | 4201 (58.1%) | 3632 (56.4%) | 0.01 | 8117 (58.3%) | 6766 (56.1%) | <0.01 |
| Not marrieda | 2795 (38.7%) | 2544 (39.5%) | 4961 (35.6%) | 4507 (37.4%) | ||
| Missing | 235 (3.2%) | 263 (4.1%) | 846 (6.1%) | 793 (6.6%) | ||
| Cancer grade (%) | ||||||
| 1 | 136 (1.9%) | 131 (2.0%) | <0.01 | 63 (0.5%) | 25 (0.2%) | <0.01 |
| 2 | 709 (9.8%) | 627 (9.7%) | 2219 (15.9%) | 498 (4.1%) | ||
| 3–4 | 1742 (24.1%) | 1902 (29.5%) | 7451 (53.5%) | 7586 (62.9%) | ||
| Cell type not determined | 4644 (64.2%) | 3779 (58.7%) | 4191 (30.1%) | 3957 (32.8%) | ||
| Surgery on primary site (%)b | ||||||
| Yes | 2533 (35.0%) | 2219 (34.5%) | 0.72 | 1618 (11.6%) | 1227 (10.2%) | <0.01 |
| No | 4654 (64.4%) | 4184 (65.0%) | 12,226 (87.8%) | 10,773 (89.3%) | ||
| Missing | 44 (0.6%) | 36 (0.6%) | 80 (0.6%) | 66 (0.5%) | ||
| Nephrectomy or prostatectomy (%) | ||||||
| Yes | 2384 (33.0%) | 2103 (32.7%) | 0.70 | 200 (1.4%) | 244 (2.0%) | <0.01 |
| No | 4847 (67.0%) | 4336 (67.3%) | 13,724 (98.6%) | 11,822 (98.0%) | ||
| Radiation (%) | ||||||
| Yes | 2160 (29.9%) | 1733 (26.9%) | <0.01 | 3111 (22.3%) | 2762 (22.9%) | <0.01 |
| No | 4986 (69.0%) | 4667 (72.5%) | 10,662 (76.6%) | 9235 (76.5%) | ||
| Missing | 85 (1.2%) | 39 (0.6%) | 151 (1.1%) | 69 (0.6%) | ||
| Residence in state with cancer clinical trial lawsc | ||||||
| Yes | 5527 (76.4%) | 4934 (76.6%) | 0.79 | 10,803 (77.6%) | 9397 (77.9%) | 0.57 |
| No | 1704 (23.6%) | 1505 (23.4%) | 3121 (22.4%) | 2669 (22.1%) | ||
a
Includes single, divorced, and widowed.
b
Includes surgeries, local tumor excision or destruction, and laser ablation.
c
Signifies laws requiring health plans to cover patient care costs in cancer clinical trials.